Secukinumab
Brand name: Cosentyx Sensoready (2 Pens)
Rank #51 of 500 drugs by total cost
$347.7M
Total Cost
45,496
Total Claims
$347.7M
Total Cost
2,277
Prescribers
$7,643
Cost per Claim
393
Beneficiaries
47,119
30-Day Fills
$153K
Avg Cost/Provider
20
Avg Claims/Provider
About Secukinumab
Secukinumab (sold as Cosentyx Sensoready (2 Pens)) was prescribed 45,496 times by 2,277 Medicare Part D providers in 2023, costing the program $347.7M. At $7,643 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 48 | Insulin Detemir (Levemir Flexpen) | $376.5M | 548,216 |
| 49 | Aripiprazole (Aripiprazole) | $373.1M | 1,494,971 |
| 50 | Apalutamide (Erleada) | $369.2M | 24,956 |
| 51 | Secukinumab (Cosentyx Sensoready (2 Pens)) | $347.7M | 45,496 |
| 52 | Upadacitinib (Rinvoq) | $346.0M | 51,469 |
| 53 | Abiraterone Acetate (Abiraterone Acetate) | $345.0M | 122,643 |
| 54 | Icosapent Ethyl (Vascepa) | $334.9M | 692,252 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology